Description
The Neurobiology of Aging and Alzheimer Disease in Down Syndrome
Coordinators: Head Elizabeth, Lott Ira
Language: EnglishSubjects for The Neurobiology of Aging and Alzheimer Disease in Down...:
Keywords
Actigraph; Aging; Alzheimer’s disease; Alzheimer's disease; Amyloid; Amyloid beta; Amyloid PET; Anxiety; Arterial spin labeling; Autophagy; Beta-amyloid; Biomarker; Biomarkers; Blood vessels; Bone; Brain; Cardiovascular; Cerebral amyloid angiopathy; Cerebrospinal fluid; Cerebrovascular; Chemokines; Cholinergic; Clinical trials; Cytokines; Dementia; Depression; Development; Diffusion MRI; Down syndrome; Extracellular vesicles; FDG PET; Fetal; FLAIR; Functional MRI; Gait; Genetics; Genomics; High risk individuals; History; Immunotherapy; Magnetic resonance imaging; Mass spectrometry; Menopause; Mental illness; Mental status; Metabolomic; Microbleeds; Microglia; Mild cognitive impairment; MR spectroscopy; mTOR; Muscle tone; Neuroimaging; Neurological exam; Neuropathology; Neuropsychology; Obstructive sleep apnea; Oxidative stress; Pathways; Perivascular spaces; PET Imaging; Pharmacotherapy; Plasma; Polysomnography; Precision medicine; Proteomic; Psychosis; Reflexes; Regression syndrome; Seizures; SIMOA; Sleep; Sleep apnea; Swallowing; Synuclein; Systems biology; Tau; Tau PET; TDP-43; Therapeutics; Thyroid; Trisomy; Trisomy 21; White matter hyperintensities
352 p. · 21.5x27.6 cm · Paperback
Description
/li>Contents
/li>Biography
/li>Comment
/li>
1. Introduction 2. Alzheimer’s neuropathology in Down syndrome: From gestation to old age 3. The contribution of inflammation to Alzheimer’s disease in Down syndrome 4. The role of cerebrovascular disease in aging and Alzheimer’s disease among people with Down syndrome 5. Oxidative stress and mTOR in Down syndrome brain: Link to Alzheimer’s dysmetabolism, neuropathology, and possible therapies 6. Fluid biomarkers for Alzheimer’s disease in Down syndrome: Current status and novel trends 7. Proteomic and metabolomic biomarkers of Alzheimer’s disease: Opportunities to advance precision medicine and clinical trials 8. Magnetic resonance imaging biomarkers for cognitive decline in Down syndrome 9. PET imaging in Down syndrome and Alzheimer’s disease 10. Genetics of Alzheimer’s disease in adults with Down syndrome 11. Co-occurring medical conditions in aging adults with Down syndrome 12. Sleep in aging adults with Down syndrome and its association with Alzheimer’s disease 13. Contributions of the neurological examination to the diagnosis of dementia in Down syndrome 14. Psychiatric issues in aging and dementia 15. Cognitive profile of aging and dementia 16. Clinical trials for Alzheimer’s disease in Down syndrome 17. Future directions
Index
Dr. Lott is an Emeritus Professor of Pediatrics and Neurology at the University of California, Irvine. His training was at the Massachusetts General Hospital, Harvard Medical School and he was appointed as the first Clinical Director of the Eunice Kennedy Shriver Center for people with intellectual disability. Since his recruitment to UCI in 1983, he has served as Division chief in pediatric neurology, Chair of Pediatrics and Associate Dean for Clinical Neuroscience. Dr. Lott’s research on development and aging in people with Down syndrome has been continuously funded by the National Institutes of Health for over 25 years. He has received award recognition for his work at the international, national and state levels. Having trained generations of medical students and resident physicians, Dr. Lott’s approach focuses on the intersection between neuroscience and clinical practice.
- Discusses the complexities involved with aging and Alzheimer’s disease in Down syndrome
- Summarizes the neurobiology of aging that requires management in adults with DS and leads to healthier aging and better quality of life into old age
- Serves as learning tool to orient researchers to the key challenges and offers insights to help establish critical areas of need for further research